Is there an interest in repeating the vaginal administration of dinoprostone ( Propess® ) , to promote cervical ripening of pregnant women at term? - RE-DINO

CHU de LIMOGES0 个研究点目标入组 360 人开始时间: 2016年4月22日最近更新: 2022年5月23日

试验速览

暂无简介。

•- Age = 18 years.
•- Term pregnancy> 37 weeks
•- Current Trigger medically indicated
•- Patients who have had the establishment of a first Propess®, within 24 to 36 hours (before signing the consent)
•- Cephalic presentation
•- Unfavorable cervical conditions (Bishop score <6), one hour before inclusion
•- Intact membranes
•- Affiliated with the French social security system
•- Having signed the consent form.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 360
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Multiple pregnancy
•- Uterus scar
•- Contraindications to epidural anesthesia
•- Contraindications to Propess®: recent history of pelvic inflammatory disease; hypersensitivity to prostaglandins
•- Contraindications to Syntocinon: Hypersensitivity to oxytocin, cardiovascular disorders and severe toxemia of pregnancy.
•- Contraindications to vaginal delivery
•- Premature Rupture of Membranes (PROM)
•- Intra Uterine Growth retardation (IUGR) < 3rd percentile
•- Macrosomia > 97th percentile
•- Impaired fetal heart rate
•- Fetal Death In Utéro (IUFD)
•- Patient under guardianship, curatorship or safeguard justice

发起方

CHU de LIMOGES